At a glance
- Company
- Lunit
- Ticker
- KRX: 328130.KQ
- Announcement
- Partnership
- Location
- Seoul, South Korea
Key figures
- Contract duration
- three years
- Chest X-ray images to be analyzed
- approximately 1 million
People
- Brandon SuhCEO of Lunit
Products and programs
Following last year’s success, Lunit secures a second contract with Dr. Sulaiman Al Habib Medical Group, analyzing 1 million chest X-rays over three years
SEOUL, South Korea, March 6, 2025 -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced a second agreement with Cloud Solutions, a subsidiary of Dr. Sulaiman Al Habib Medical Group (HMG), Saudi Arabia’s largest medical organization. Building on the success of their 2023 collaboration, Lunit will now supply its AI-powered chest X-ray analysis solution, Lunit INSIGHT CXR, to the Kingdom of Saudi Arabia for the next three years, analyzing approximately 1 million chest X-ray images.
This latest contract expands on Lunit’s initial partnership with HMG, which introduced Lunit INSIGHT MMG to support breast cancer screening across the Kingdom. With Lunit INSIGHT CXR, the collaboration aims to enhance diagnostic precision and efficiency in detecting critical chest abnormalities, including lung cancer, tuberculosis, and pneumonia.
“We are proud to further strengthen our collaboration with Dr. Sulaiman Al Habib Medical Group,” said Brandon Suh, CEO of Lunit. “This second contract underscores the value of our AI solutions and reflects our shared commitment to advancing healthcare through innovation.”
Revolutionizing Diagnostics with AI
Lunit INSIGHT CXR leverages advanced AI technology to detect chest abnormalities with high accuracy, enabling faster, more precise diagnoses and optimized clinical workflows. Its deployment aligns with Saudi Arabia’s Vision 2030 initiative, which emphasizes healthcare innovation and digital transformation.
Driving Regional Growth in AI Healthcare
According to Markets and Data, Saudi Arabia’s AI in medical diagnostics market is projected to witness a compound annual growth rate (CAGR) of 26.97%, growing from USD 34.37 million in 2023 to USD 231.77 million by 2031. This second contract strengthens Lunit’s foothold in a region poised for rapid adoption of AI-powered healthcare solutions.
“Expanding our partnership with HMG demonstrates the growing demand for AI-powered diagnostics across the Middle East,” added Suh. “We are excited to continue supporting Saudi Arabia’s healthcare transformation while addressing key challenges such as radiologist shortages.”
If you detect any issues, problems, or errors in this press release content, kindly contact [email protected] to notify us (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). We will respond and rectify the situation in the next 8 hours.
In brief
Lunit announced a second agreement with Cloud Solutions, a subsidiary of Dr. Sulaiman Al Habib Medical Group, to provide its Lunit INSIGHT CXR chest X-ray analysis system in Saudi Arabia. The company says the three-year contract covers analysis of approximately 1 million chest X-ray images. The deal follows a 2023 collaboration that brought Lunit INSIGHT MMG breast cancer screening to the Kingdom. Lunit says the new deployment is intended to help identify abnormalities including lung cancer, tuberculosis and pneumonia, and to support diagnostic workflows. CEO Brandon Suh said the expanded relationship reflects shared interest in healthcare innovation. The release also connects the deployment with Saudi Arabia’s Vision 2030 initiative and describes it as part of the company’s regional growth in AI-based healthcare.
Key takeaways
- Lunit secured a second contract with Cloud Solutions, a subsidiary of Dr. Sulaiman Al Habib Medical Group.
- The three-year agreement covers approximately 1 million chest X-ray images in Saudi Arabia.
- The solution is intended to assist detection of lung cancer, tuberculosis and pneumonia.
- The earlier collaboration involved Lunit INSIGHT MMG for breast cancer screening.
Earlier from Lunit
- Real-World Validation: Lunit AI Proven Successful in 1-Year Breast Cancer Screening Deployment
- Lunit Inks Partnership with Salud Digna to Advance AI in Medical Imaging
- Lunit Announces Collaboration with AstraZeneca to Develop AI-Powered Digital Pathology Risk Assessment Tools for NSCLC
- Lunit Shows Promise of AI in Predicting Immunotherapy Response for Rare Cancer Patients at SITC 2024
- Lunit AI Predicts Breast Cancer Risk Up to 6 Years in Advance
